Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTLOKXP)

• DTT Name: Gastric H(+)/K(+) ATPase (Proton pump) DTT Info
• Gene Name: ATP4A

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexlansoprazole	DM1DBV5	Erosive esophagitis	DA25.0	Approved	[1]
Esomeprazole	DM7BN0X	Cystic fibrosis	CA25	Approved	[1]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[1]
Pantoprazole	DMSVOCZ	Gastrinoma	2C10.1	Approved	[1]
Vonoprazan	DMO6315	Helicobacter infection	DA42-DA63	Approved	[2]

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RQ-00000004	DM9T8OF	Gastroesophageal reflux disease	DA22.Z	Phase 3	[3]
AZD-0865	DMM0N1F	Gastrointestinal disease	DE2Z	Phase 2	[4]
S-tenatoprazole	DMJ1DIB	Peptic ulcer	DA61	Phase 2	[5]
YH-4808	DMCHFB0	Duodenal ulcer	DA63	Phase 2	[6]

10 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LEMINOPRAZOLE	DMBKNJT	Ulcerative colitis	DD71	Discontinued in Preregistration	[7]
PUMAPRAZOLE	DMB069L	Duodenal ulcer	DA63	Discontinued in Phase 3	[8]
SKF-96067	DMXW1Y3	Peptic ulcer	DA61	Discontinued in Phase 3	[9]
AR-H047108	DMBTG8J	Duodenal ulcer	DA63	Discontinued in Phase 2	[10]
SORAPRAZAN	DMCS8FM	Peptic ulcer	DA61	Discontinued in Phase 2	[11]
TY-11345	DMQWA2R	Peptic ulcer	DA61	Discontinued in Phase 2	[12]
CS-526	DMXKB8V	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 1	[13]
SKF-97574	DM1XEUV	Peptic ulcer	DA61	Discontinued in Phase 1	[9]
Saviprazole	DM79E6W	Peptic ulcer	DA61	Terminated	[14]
SK&F-95601	DMRM7H0	Peptic ulcer	DA61	Terminated	[15]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
YH-1238	DM6FEMV	Discovery agent	N.A.	Investigative	[16]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008
• [3] N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9.
• [4] Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205.
• [5] Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62.
• [6] Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704.
• [7] Vasoinhibitory effect of leminoprazole, a H+,K(+)-ATPase inhibitor, on rat aortic rings. Gen Pharmacol. 1996 Jan;27(1):117-21.
• [8] Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Heli... Aliment Pharmacol Ther. 1999 Jan;13(1):27-34.
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] Early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity in dogs treated with AR-H047108, an imidazopyridine proton pump inhibitor.Toxicol Pathol.2008 Jul;36(5):727-37.
• [11] Soraprazan: setting new standards in inhibition of gastric acid secretion.J Pharmacol Exp Ther.2007 Jun;321(3):866-74.
• [12] Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals. Jpn J Pharmacol. 1993 Aug;62(4):363-71.
• [13] Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]... J Pharmacol Exp Ther. 2007 Oct;323(1):308-17.
• [14] Gastric acid inhibitory profile of saviprazole (HOE 731) compared to omeprazole. Pharmacology. 1991;43(6):293-303.
• [15] 2-[[(4-Amino-2-pyridyl)methyl]sulfinyl]benzimidazole H+/K+-ATPase inhibitors.The relationship between pyridine basicity, stability, and activity.J Med Chem.1989 Aug;32(8):1970-7.
• [16] Compositions for improving gastrointestinal nutrient and drug absorption